AMIDEBIO Awarded SBIR Phase I Grant to Develop Novel Glucose Responsive Insulin Therapeutics

AMIDEBIO, LLC, a privately-held biopharmaceutical company, announced today that it has received $300,000 in funding through a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for AmideBio’s Glucose Responsive Insulin (GRI) program. Read the full press release.